Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, and Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced a new agreement to commercialize the Moderna Covid Vaccine across Central Eastern Europe and Israel.
Poland, the Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Ukraine, Moldova, Albania, Bosnia, and Herzegovina, Kosovo, North Macedonia, Latvia, Lithuania, Serbia, Montenegro, and Israel are all covered by the pact.
Medison also has a corporate venture arm with a dedicated research and assessment team with extensive scientific and business knowledge. Moderna’s mRNA platform has enabled the creation of treatments and vaccines for infectious illnesses, immuno-oncology, rare illnesses, cardiovascular disorders, and auto-immune disorders, thanks to continual improvements in basic and applied mRNA research, delivery technology, and manufacturing.There are currently 24 development programs in these therapeutic areas, with 13 of them having entered the clinic. For the previous six years, Science has rated Moderna as a top biopharmaceutical employer.